BIO President Feldbaum To Speak, Mar. 19 in Masur Auditorium, March 16, 2004 NIH Record

BIO President Feldbaum To Speak, Mar. 19 in Masur Auditorium

On Friday, Mar. 19, the National Cancer Institute will present a talk by Carl B. Feldbaum, president of the Biotechnology Industry Organization (BIO), titled, "Biotechnology and NCI: Partners in Bringing Patients the Next Generation of Cancer Therapy." The talk will be held from 2 to 3 p.m. in Masur Auditorium, Bldg. 10, as part of the NCI Director's Seminar Series.

Feldbaum will provide an overview of the biotechnology industry, including its record of developing cancer therapies and also discuss the importance of collaboration between industry, NCI and academic centers. He is also expected to discuss such issues as conflict of interest and the taxpayer's fair rate of return on the investment in research.

Carl Feldbaum

Feldbaum has been a leader in biotechnology and government. After receiving his bachelor's degree in biology from Princeton University and his law degree from the University of Pennsylvania, he was assistant special prosecutor on the Watergate case. He was later chief of staff to Sen. Arlen Specter (R-PA), assistant to the Secretary of Energy, and inspector general for defense intelligence in the Department of Defense. Feldbaum eventually founded and was president of the Palomar Corp., a national security think tank in Washington, D.C.

Feldbaum was honored with the Distinguished Civilian Service Medal from Defense Secretary Harold Brown in 1979 and received the Best of Biotech 1995 — Special Recognition for an Individual award, given by 140 biotechnology CEOs "for leadership of the Biotechnology Industry Organization, which has emerged as a truly effective platform for the industry." He is a member of the Biotechnology Hall of Fame and received the Christopher Medal for his book Looking the Tiger in the Eye: Confronting the Nuclear Threat, designated by the New York Times as a notable book of the year in 1988.

As president of BIO, Feldbaum represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in the U.S. and 33 other countries. BIO members are involved in the research and development of health care, agricultural, industrial and environmental biotechnology products.

Feldbaum's lecture will be webcast at http://videocast.nih.gov. Sign language interpretation will be provided.

The next lecture in the NCI Director's Seminar Series, scheduled for Sept. 16, will feature Dr. Julie Gerberding, director of the Centers for Disease Control and Prevention, speaking from 1 to 2 p.m. in Masur Auditorium.

For more information, or for reasonable accommodation, contact Kate Haessler at (301) 348-1662 or the Federal Relay at 1-800-877-8339. More information about the series can be found at http://cancer.gov/directorscorner.

Up to Top